Health Resources International Ltd

hri.uk.com

Health Resources International Limited was established in 2003 in the United Kingdom. The company was originally set up to supply UK organizations (both public and private) with hospital consultants and specialists from Eastern Europe. We have dealt with consultants, junior doctors and general practitioners (primary care physicians), supplying them on a fixed, short term, sessional, rotational or locum basis. Since incorporation we have recruited a couple of hundreds of medical professionals in the UK, the majority of which have been consultants in permanent positions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

news image

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

news image

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More

Industrial Impact

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

news image

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More

Industrial Impact

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

news image

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More
news image

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

news image

Medical

RATIO THERAPEUTICS LAUNCHES TO DISCOVER AND DRIVE EARLY CLINICAL DEVELOPMENT OF BEST-IN-CLASS TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCERS

Ratio Therapeutics | June 13, 2022

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...

Read More
news image

Industrial Impact

GEOVAX ANNOUNCES $10 MILLION PRIVATE PLACEMENT

GeoVax, Inc. | January 15, 2022

GeoVax Labs, Inc. a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. Each share of common stock ...

Read More
news image

Industrial Impact

MYCOWORKS SECURES STRATEGIC INVESTMENT FROM GM VENTURES TO DEVELOP FINE MYCELIUM MATERIALS FOR SUSTAINABLE AUTOMOTIVE INTERIORS

MycoWorks | October 19, 2022

Biotechnology company MycoWorks announced today its newest investor GM Ventures, the investment arm of General Motors Co. and their long-term agreement to co-develop Fine Mycelium™ materials for potential use in a range of applications within automotive design. MycoWorks' collaboration with GM marks the exploration of its entry into one of the largest end-use markets for leather and demonstrates the significant opportunity to create more sustainable materials for the automotive space.<...

Read More